Form 4: Neurocrine Biosciences CSO Executes Stock Option Sale
Statement of Changes in Beneficial Ownership
Chief Scientific Officer Jude Onyia exercised options and sold 11,000 shares of Neurocrine Biosciences common stock.
Summary
- Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences, exercised options to acquire 11,000 shares at $84.74 per share.
- Following the acquisition, the officer sold 11,000 shares at a weighted average price of $155.5332 per share.
- The transactions were executed on May 27, 2026, pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
- Post-transaction, the reporting person retains beneficial ownership of 25,846 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event; the sale is a routine exercise of vested equity compensation conducted through a pre-established, compliant trading plan.
Positives
- The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.
- The officer maintains a significant remaining equity stake of 25,846 shares in the company.
Negatives
- The sale represents a reduction in the officer's direct equity holdings in the company.
Risks
- The sale was conducted under a Rule 10b5-1 plan, which limits the officer's ability to modify or amend the trading strategy once adopted.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that executive stock sales executed via 10b5-1 plans are standard practice in the biotechnology sector, allowing insiders to diversify holdings while mitigating concerns regarding non-public information usage.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for C-suite executives at large-cap biotech firms like Amgen, Biogen, and Vertex to ensure regulatory compliance during equity liquidation.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned and represents a standard exercise of compensation-related equity.
Next Steps
- Reporting person will continue to hold remaining 25,846 shares.
Key Dates
| Date | Description |
|---|---|
| 2022-11-29 | Initial vesting date for the stock options exercised. |
| 2026-02-25 | Adoption date of the Rule 10b5-1 trading plan. |
| 2026-02-27 | Purchase date of 176 shares via Employee Stock Purchase Plan. |
| 2026-05-27 | Date of option exercise and subsequent share sale. |
| 2026-05-28 | Filing date of the Form 4. |
| 2031-11-29 | Expiration date of the non-qualified stock options. |
Keywords
NBIX, Neurocrine Biosciences, Insider Trading, Form 4, Chief Scientific Officer, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.